Journavx, developed by Vertex Pharmaceuticals Incorporated ... in Emergency Medicine and Pain Medicine in San Diego and Vertex Acute Pain Steering committee member. “I believe Journavx could redefine ...

Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert therapeutic changes into the genome, today ...

Net revenues of $25.1 million in Q1 2025, a 29% increase compared to $19.5 million in Q1 2024, driven by strong demand for Cannara's premium-grade cannabis products.Record Market Share: Achieved ...

Nondividend payers, such as the fund's positions in Vertex Pharmaceuticals and Royal Caribbean ... and Capital International Investors since early 2014. Longest-tenured manager Alan Berro, who ...

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Zimislecel (formerly VX-880), has shown remarkable early results, setting the stage for the therapy to enter a pivotal-stage trial. At 23.8 times forward earnings, Vertex stock trades in line with ...